NCT06396091 - A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Metastatic Pancreatic Adenocarcinoma

Interventions

DRUG

zolbetuximab

Zolbetuximab will be administered intravenously on day 1 then every two weeks.

DRUG

mFOLFIRINOX

Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

20016

RECRUITING

Johns Hopkins Hospital, Washington D.C.

40202

RECRUITING

Norton Cancer Institute, Louisville

92835

RECRUITING

Providence Medical Foundation, Fullerton

98101

RECRUITING

Virginia Mason Medical Center, Seattle

98405

RECRUITING

Multicare Health System Research, Tacoma

99204

WITHDRAWN

MultiCare Deaconess & Blood Specialty Center, Spokane

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY